January 24, 2017 3:11 PM ET

Biotechnology

Company Overview of aTyr Pharma, Inc.

Company Overview

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and clinical development of Physiocrine-based therapeutics for patients suffering from severe and rare diseases. The company develops Resolaris, which is in Phase Ib/II clinical trials for treating adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic myopathy with an immune component; patients with early onset FSHD; and adult patients with limb-girdle muscular dystrophy 2B or FSHD. In addition, the company is developing iMod.Fc, a preclinical immuno-modulatory domain program. The company was founded in 2005 and is headquartered in San Diego, California.

3545 John Hopkins Court

Suite 250

San Diego, CA 92121

United States

Founded in 2005

55 Employees

Phone:

858-731-8389

Fax:

858-731-8394

Key Executives for aTyr Pharma, Inc.

Chief Executive Officer and Director
Age: 56
Total Annual Compensation: $472.8K
Senior Advisor
Age: 58
Total Annual Compensation: $291.2K
Compensation as of Fiscal Year 2015.

aTyr Pharma, Inc. Key Developments

FDA Grants Fast Track Designation for Atyr's Resolaris to Treat Limb Girdle Muscular Dystrophy 2B and Removes Partial Clinical Hold for Resolaris

Tyr Pharma, Inc. announced that its product candidate Resolaris was granted Fast Track designation by the U.S. Food and Drug Administration for the treatment of limb girdle muscular dystrophy 2B (LGMD2B), making it the first known therapeutic candidate for the treatment of LGMD2B to receive the designation. In addition, the FDA removed its partial clinical hold on a dosing ceiling for Resolaris in clinical trials. aTyr previously announced results from a completed Phase 1b/2 open-label, intra-patient dose escalation trial testing doses of Resolaris up to 3.0 mg/kg biweekly in patients with LGMD2B. Based on the clinical trials completed to date, Resolaris has demonstrated a favorable safety profile without signs of immuno-suppression of circulating immune cells. 78% of the LGMD2B patients in the trial (7 of 9) recorded increases in their muscle function at 14 weeks as measured by manual muscle test, a validated assessment tool. Overall, the LGMD2B patients had a mean increase of MMT scores from baseline of 6.2%.

aTyr Pharma, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-12-2017 09:00 AM

aTyr Pharma, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-12-2017 09:00 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: John D. Mendlein, Chief Executive Officer and Director.

aTyr Pharma, Inc. Presents at East/West CEO Conference, Jan-08-2017 01:30 PM

aTyr Pharma, Inc. Presents at East/West CEO Conference, Jan-08-2017 01:30 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103, United States.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
November 18, 2016
--
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Bloomberg L.P. United States
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact aTyr Pharma, Inc., please visit www.atyrpharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.